article = {SCR-2024-2-101}
title = {Splenectomy before Allogeneic Hematopoietic Stem-cell Transplantation for Myelofibrosis: Two Cases}
journal = {Surgical Case Reports}
year = {2024}
issn = {2613-5965}
doi = {http://dx.doi.org/10.31487/j.SCR.2024.02.01}
url = {https://www.sciencerepository.org/splenectomy-before-allogeneic-hematopoietic_SCR-2024-2-101 
author = {Zhengxiang Yang,Aibin Zhang,Xiaoyu Lai,Luxin Yang,Yishan Ye,Qingna Guo,Yibo Wu,He Huang,Yi Luo,Lizhen Liu,}
keywords = {Splenectomy, myelofibrosis, massive splenomegaly, allogeneic hematopoietic stem cell transplantation}
abstract ={Myelofibrosis (MF) is a clonal hematological malignancy characterized by splenomegaly, systemic symptoms, myelofibrosis, and a tendency to transform into acute leukemia. MF treatment includes anemia treatment, hydroxyurea, JAK inhibitors (JAKi) allogeneic hematopoietic stem cell transplantation (allo-HSCT), among which allo-HSCT is the only possible cure for MF. The effect of splenomegaly on the prognosis of allo-HSCT with myelofibrosis and whether splenic treatment is needed before transplantation has not been determined. A recent retrospective study from the EBMT working group found that splenectomy significantly reduced transplant-related non-recurrent mortality and did not increase the risk of disease recurrence in MF patients with pre-transplant splenomegaly. Two cases of MF splenectomy combined with allo-HSCT are reported.}